Dariohealth Corp SEC Filings

Titan Trust 2024 I reports it holds 0 shares of DarioHealth Corp. common stock, representing 0% of the class after disposing of all previously held shares. The filing states the Reporting Person disposed during the three months ended 09/30/2025 of 2,499,618 shares that were issued on 08/14/2025 upon a cashless exercise of a warrant dated 02/15/2024. The filing notes those share figures are shown on a pre-20-to-1 reverse stock split basis implemented on 08/28/2025. The statement affirms the securities were not acquired to influence control of the issuer.

DarioHealth Corp. filed a Form D notice claiming a Rule 506(b) exemption for an equity offering that raised $17,500,000, with no remaining securities to be sold. The filing lists the first sale date as 2025-09-22 and shows 10 total investors. Offered securities include equity and options/warrants to acquire other securities. The issuer indicates the offering will not last more than one year and the minimum investment accepted is $0. The company reports $0 in sales commissions and finders' fees and $0 of proceeds paid to named executives or directors. Key officers and directors are identified with the principal place of business in New York, NY.

DarioHealth Corp. (DRIO) filed an Form 8-K reporting amendments to multiple certificates of designation for its preferred stock series. The filing lists amended or restated certificates for Series A-1, C, C-2, D, D-1, D-2, and D-3 preferred shares and includes an interactive data cover page. The document also references written and soliciting communications under SEC Rules 425, 14a-12, 14d-2(b), and 13e-4(c). The filing is dated September 18–19, 2025 and notes the company’s common stock trades on NASDAQ Capital Market. The filing text lists exhibits but does not disclose the economic or governance terms of the amended designations within the provided excerpt.

Steven Nelson, President and CCO of DarioHealth Corp. (DRIO), reported a non-derivative acquisition on 09/11/2025 of 30,000 restricted shares granted at $0. The award vests on the last day of the second-year anniversary after the grant date. Following the transaction and a 20-for-1 reverse stock split effected on August 28, 2025, Nelson beneficially owns 34,750 shares. The Form 4 was signed on 09/15/2025.

Adam K. Stern, a director of DarioHealth Corp. (DRIO), reported a restricted stock award of 20,000 shares granted on 09/11/2025 at a $0 price. The award is scheduled to vest on the last day of the second-year anniversary after the grant date. Following the reported transaction and reflecting a 20-for-1 reverse stock split effected on August 28, 2025, the filing shows 29,717 shares beneficially owned directly and 6,146 shares beneficially owned indirectly through AKS Family Partners L.P. The filing also discloses indirect beneficial ownership of 123,763 Series-C preferred shares. The form is signed by Mr. Stern on 09/15/2025.

Lawrence B. Leisure, a director of DarioHealth Corp. (DRIO), reported the acquisition of 20,000 shares of common stock as a restricted share award on 09/11/2025. The award is recorded at a price of $0 and will vest on the last day of the two-year anniversary after the grant date, so the shares are not immediately transferable. Following the reporting adjustments for a 20-for-1 reverse stock split effective August 28, 2025, the filing lists 12,900 shares as beneficially owned indirectly through NearWater Growth, LLC. The Form 4 was signed by the reporting person on 09/15/2025.

DarioHealth Corp. (DRIO) director Yoav Shaked reported a restricted share award granted and recorded on 09/11/2025. The filing shows an acquisition of 20,000 shares of common stock at a reported price of $0, structured to vest in two equal installments on the last day of each successive annual anniversary after the grant date over a two-year period. After accounting for a 20-for-1 reverse stock split effected on August 28, 2025, the number of shares beneficially owned by Mr. Shaked is shown as 32,810.

The report also discloses indirect ownership of 84 shares held by the reporting person’s spouse, with the reporting person disclaiming beneficial ownership of those shares. The form is signed by Yoav Shaked on 09/15/2025.

Raphael Erez, who is listed as Chief Executive Officer and a director of DarioHealth Corp. (DRIO), reported a non‑derivative award on this Form 4. On 09/11/2025 he was granted 60,000 restricted shares at a stated price of $0; the award vests in two equal installments on the last day of each successive annual anniversary over a two‑year period. Following the grant and reflecting a 20‑for‑1 reverse stock split effected August 28, 2025, the filing reports total beneficial ownership of 156,853 common shares. The filing also discloses indirect ownership of 1,894 shares through Dicilyon Consulting and Investment Ltd. The report is signed by Mr. Erez on 09/15/2025.